The BioPharm Brief: Reviews, Receptors, and Results

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today's stories all center on one theme: what it takes to move promising therapies closer to patients. Whether it's navigating global regulatory review, expanding treatment options in oncology, or testing an entirely new approach to cardiovascular disease, these updates show how development success depends on much more than strong science alone.

Our first story focuses on biosimilars.

Polpharma Biologics and Fresenius Kabi announced that both the FDA and European Medicines Agency have accepted for review PB016, a proposed biosimilar to vedolizumab, the biologic marketed as Entyvio for ulcerative colitis and Crohn's disease. Acceptance for review doesn't mean approval, but it represents an important regulatory milestone and reflects the agencies' determination that the applications are complete enough for formal evaluation.

If approved, PB016 would add another option to the growing biosimilar market, where competition continues to expand patient access while helping reduce healthcare costs. The candidate has already completed both Phase 1 and Phase 3 clinical studies, and Polpharma will manufacture the product while Fresenius Kabi oversees commercialization in most global markets.

Next, we move to oncology.

The European Commission has approved Datroway, also known as datopotamab deruxtecan, as the first TROP2-directed antibody-drug conjugate for first-line treatment of certain patients with metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy. The approval broadens access to an important new treatment option for one of the most aggressive forms of breast cancer.

The decision also reflects the continued momentum behind antibody-drug conjugates. By combining the targeting precision of monoclonal antibodies with potent cytotoxic payloads, ADCs continue to expand into earlier lines of therapy across multiple cancer types, demonstrating how this drug class is evolving beyond later-stage disease.

Finally, we turn to cardiovascular disease.

Novo Nordisk reported phase 3 results from the ZEUS trial evaluating ziltivekimab, an investigational monoclonal antibody targeting interleukin-6 inflammation in patients with cardiovascular disease and chronic kidney disease. While the therapy successfully reduced inflammatory biomarkers, the study did not achieve its primary endpoint of reducing major adverse cardiovascular events compared with placebo.

Although disappointing, the results provide valuable insight into the complexity of translating biomarker improvements into meaningful clinical outcomes. The findings also underscore an important lesson for drug developers: biological activity alone does not always predict clinical benefit. Novo Nordisk said additional cardiovascular studies involving ziltivekimab remain ongoing.

That's all for today's BioPharm Brief.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

• FDA and EMA review acceptance moves a new vedolizumab biosimilar one step closer to market.
• Europe expands first-line treatment options for metastatic triple-negative breast cancer with a new TROP2-directed ADC.
• Novo Nordisk's Phase 3 cardiovascular study highlights the ongoing challenge of translating promising biomarkers into improved patient outcomes.